Company intelligence / Profile preview

ViCentra

Utrecht, Netherlands

Ownership: Private
Development stage: Other

Overview

ViCentra has demonstrated strong early commercial uptake of its Kaleido insulin patch pump in Germany, France, and the Netherlands. The system is CE Marked and has begun market launches, with planned rollouts for next-generation products and further clinical integration with automated insulin delivery algorithms in partnership with Diabeloop and Dexcom. Initial sales have exceeded expectations and are limited mainly by manufacturing capacity, not demand[1][2][3][6].

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Diabeloop (integrated automated insulin delivery algorithms)Dexcom (CGM sensor integration)

Beyond the preview

Go deeper on ViCentra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViCentra.

Explore the full profile